Pharming Technologies B.V.
25
2
6
13
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 55/100
16.0%
4 terminated/withdrawn out of 25 trials
76.5%
-10.1% vs industry average
20%
5 trials in Phase 3/4
62%
8 of 13 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (25)
Efficacy of KL1333 in Adult Patients With Primary Mitochondrial Disease
Role: lead
Pediatric Patients Aged 1 to 6 Years With APDS
Role: lead
Pediatric Patients Aged 4 to 11 Years With APDS
Role: lead
Recombinant Human C1 Esterase Inhibitor (Conestat Alfa) in the Prevention of Acute Ischemic Cerebral and Renal Events After Transcatheter Aortic Valve Implantation
Role: collaborator
Extension to the Study of Efficacy of CDZ173 in Patients With APDS/PASLI
Role: lead
Long-term Safety and Efficacy of Leniolisib in PIDs With Immune Dysregulation
Role: lead
Leniolisib for Immune Dysregulation in PIDs
Role: lead
Leniolisib for Immune Dysregulation in CVID
Role: lead
C1 Inhibitor Registry in the Treatment of Hereditary Angioedema (HAE) Attacks
Role: lead
Patient Registry to Evaluate the Real-world Safety of Ruconest®
Role: lead
Prevention of Acute Kidney Injury in Patients With NSTEMI
Role: lead
Safety of Ruconest in 2-13 Year Old Hereditary Angioedema (HAE) Patients
Role: lead
Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19
Role: lead
An Open-Label Study to Assess the Safety & Efficacy of Leniolisib in Japanese Patients With APDS
Role: lead
Conestat Alfa in the Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19
Role: collaborator
RUCONEST® as a Therapeutic Strategy to Reduce the Incidence of Delayed Graft Function
Role: collaborator
Recombinant Human C1 Esterase Inhibitor in the Prevention of Contrast-induced Nephropathy in High-risk Subjects
Role: collaborator
A Study of the Safety and Immunogenicity of Repeated rhC1INH Administration
Role: lead
A Phase 2 HAE Prophylaxis Study With Recombinant Human C1 Inhibitor
Role: lead
Efficacy, Safety and Immunogenicity Study of Recombinant Human C1 Inhibitor for the Treatment of Acute HAE Attacks
Role: lead